Dermatophytic Onychomycosis Market by Product (Nail Paint and Tablet), Route of Administration (Topical and Oral Therapy), and End User (Hospitals, Dermatology & Podiatry Clinics, Independent Pharmacies, Mail Order Pharmacies, and Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Report Number: 1043
  • Publish Date: 12-May-2018

Reports Overview

 

Onychomycosis is a fungal infection of the fingernails or toenails, wherein the bed of the nail and the plate under the surface of the nail are affected. This infection makes the nail look white, opaque, thickened, and brittle. This condition is also prevalent in stratum corneum and hair. Onychomycosis infections are caused by members of the genera Microsporum, Trichophyton, and Epidermophyton, which are known as dermatophytosis.

The global dermatophytic onychomycosis market is driven by rise in prevalence of dermatophytic onychomycosis, increase in geriatric population prone to diabetes, sedentary lifestyle, surge in number of R&D activities, and high demand for aesthetic appearing nails. However, side effects of the antifungal drugs and lack of awareness about dermatophytic onychomycosis impede the market growth. Furthermore, growth in healthcare infrastructure, rise in awareness about fungal nail infections in emerging nations, and development of innovative novel technology and combination therapies are expected to provide numerous opportunities for market expansion in the near future.

The dermatophytic onychomycosis market is segmented based on product, route of administration, end user, and region. On the basis of product, it is bifurcated into nail paint and tablet. Tablet segment is further sub-segmented into prescription and over-the-counter (OTC) tablets. Based on route of administration, the market is categorized into topical and oral therapy. Based on end user, it is segmented into hospitals, dermatology & podiatry clinics, independent pharmacies, mail order pharmacies, and drug stores. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market include Valeant Pharmaceuticals International Inc., Novartis AG, Pfizer Inc., Johnson & Johnson, Galderma S.A., Moberg Pharma AB, Allergan Plc., GlaxoSmithKline plc., Sanofi S.A., and NovaBiotics Inc.

Key Benefits

  • The study provides an in-depth analysis of the global dermatophytic onychomycosis market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Dermatophytic Onychomycosis Market Key Segments:

By Product

  • Nail Paint
  • Tablet
    • Prescription Tablets
    • Over-the-Counter (OTC) Tablets

By Route of Administration

  • Topical
  • Oral Therapy

By End User

  • Hospitals
  • Dermatology & Podiatry Clinics
  • Independent Pharmacies
  • Mail Order Pharmacies
  • Drug Stores

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA 

Table Of Content

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 DERMATOPHYTIC ONYCHOMYCOSIS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NAIL PAINT

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. TABLET

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Prescription Tablets

4.3.4.1. Market size and forecast

4.3.5. Over-The-Counter (OTC) Tablets

4.3.5.1. Market size and forecast

Chapter: 5 DERMATOPHYTIC ONYCHOMYCOSIS MARKET, BY ROUTE OF ADMINISTRATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. TOPICAL

5.2.1. Market size and forecast

5.3. ORAL THERAPY

5.3.1. Market size and forecast

Chapter: 6 DERMATOPHYTIC ONYCHOMYCOSIS MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITALS

6.2.1. Market size and forecast

6.3. DERMATOLOGY AND PODIATRY CLINICS

6.3.1. Market size and forecast

6.4. INDEPENDENT PHARMACIES

6.4.1. Market size and forecast

6.5. MAIL ORDER PHARMACIES

6.5.1. Market size and forecast

6.6. DRUG STORES

6.6.1. Market size and forecast

Chapter: 7 DERMATOPHYTIC ONYCHOMYCOSIS MARKET, BY REGION

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.2.4. North America Dermatophytic Onychomycosis Market by Product
7.2.5. North America Dermatophytic Onychomycosis Market by Route of Administration
7.2.6. North America Dermatophytic Onychomycosis Market by End User

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.3.4. Europe Dermatophytic Onychomycosis Market by Product
7.3.5. Europe Dermatophytic Onychomycosis Market by Route of Administration
7.3.6. Europe Dermatophytic Onychomycosis Market by End User

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.6. Rest of Asia-Pacific market size and forecast

7.4.4. Asia-Pacific Dermatophytic Onychomycosis Market by Product
7.4.5. Asia-Pacific Dermatophytic Onychomycosis Market by Route of Administration
7.4.6. Asia-Pacific Dermatophytic Onychomycosis Market by End User

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Saudi Arabia market size and forecast
7.5.3.3. South Africa market size and forecast
7.5.3.4. Rest of LAMEA market size and forecast

7.5.4. LAMEA Dermatophytic Onychomycosis Market by Product
7.5.5. LAMEA Dermatophytic Onychomycosis Market by Route of Administration
7.5.6. LAMEA Dermatophytic Onychomycosis Market by End User 

Chapter: 8 COMPANY PROFILES

8.1. VALEANT PHARMACEUTICALS INTERNATIONAL INC.

8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments

8.2. NOVARTIS AG

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. PFIZER INC.

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. JOHNSON & JOHNSON

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. GALDERMA S.A.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. MOBERG PHARMA AB

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. ALLERGAN PLC.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. GLAXOSMITHKLINE PLC.

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.9. SANOFI S.A.

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. NOVABIOTICS INC.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

The global dermatophytic onychomycosis market is driven by rise in prevalence of dermatophytic onychomycosis, increase in geriatric population prone to diabetes, sedentary lifestyle, surge in number of R&D activities, and high demand for aesthetic appearing nails. However, side effects of the antifungal drugs and lack of awareness about dermatophytic onychomycosis impede the market growth. Furthermore, growth in healthcare infrastructure, rise in awareness about fungal nail infections in emerging nations, and development of innovative novel technology and combination therapies are expected to provide numerous opportunities for market expansion in the near future.

There are no reviews yet.

Be the first to review “Dermatophytic Onychomycosis Market Research Report 2018”